₩15,340.00 ($11.42)

-250.00 (-1.60%)

Weekly Expected Move ±3.7%

₩14212 ₩14776 ₩15340 ₩15904 ₩16468

KSC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Sell · Power 32 · ₩644.8B mcap · 26M float · 0.262% daily turnover

Revenue

$2.07T +6.8% ▲

5Y CAGR: +8.8%

Gross Profit

$1.09T +4.0% ▲

5Y CAGR: +11.7%

Operating Income

$260.5B -7.6% ▼

5Y CAGR: +11.7%

Net Income

$175.1B +202.4% ▲

5Y CAGR: +12.2%

EPS (Diluted)

$3824.66 +170.1% ▲

5Y CAGR: +10.3%

EBITDA

$323.4B +77.6% ▲

5Y CAGR: +9.7%

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$1.51T	$1.70T	$1.82T	$1.94T	$2.07T
YoY Growth	+11.5%	+12.3%	+6.9%	+6.7%	+6.8%
Cost of Revenue	$748.2B	$797.7B	$883.9B	$888.0B	$977.4B
Gross Profit	$763.2B	$899.7B	$931.2B	$1.05T	$1.09T
Gross Margin	50.5%	53.0%	51.3%	54.2%	52.7%
R&D Expenses	$134.3B	$169.9B	$176.6B	$176.0B	$0
SG&A Expenses	$290.7B	$341.2B	$375.7B	$400.7B	$452.4B
Operating Expenses	$580.5B	$692.3B	$735.6B	$767.0B	$830.4B
Operating Income	$123.4B	$207.3B	$195.9B	$281.9B	$260.5B
Operating Margin	8.2%	12.2%	10.8%	14.6%	12.6%
Interest Expense	$10.3B	$8.4B	$14.0B	$7.6B	$13.9B
Income Before Tax	$113.4B	$154.9B	$202.5B	$115.8B	$244.6B
Tax Expense	$13.4B	$34.7B	$11.1B	$46.9B	$15.7B
Net Income	$78.7B	$102.6B	$152.7B	$57.9B	$175.1B
Net Margin	5.2%	6.0%	8.4%	3.0%	8.5%
EPS (Diluted)	$1894.69	$2466.88	$3691.68	$1416.17	$3824.66
EBITDA	$171.2B	$211.4B	$270.3B	$182.1B	$323.4B
Shares Outstanding	42M	42M	41M	41M	58M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$515.9B	$503.9B	$481.4B	$528.4B	$542.2B	$516.6B	$492.7B	$570.8B
Cost of Revenue	$0	$888.0B	$223.0B	$234.3B	$252.9B	$257.6B	$236.0B	$266.4B
Gross Profit	$515.9B	-$384.1B	$258.4B	$294.1B	$289.3B	$258.7B	$256.7B	$304.4B
Gross Margin	100.0%	-76.2%	53.7%	55.7%	53.4%	50.1%	52.1%	53.3%
R&D Expenses	$0	$137.2B	$44.1B	$46.9B	$45.3B	$50.5B	$47.7B	$50.4B
SG&A Expenses	$414.2B	-$594.9B	$420.3B	$157.0B	$113.2B	$125.0B	$108.8B	$204.9B
Operating Expenses	$414.2B	$440.8B	$420.3B	$208.8B	$208.7B	$223.9B	$208.9B	$227.8B
Operating Income	$101.7B	$63.0B	$61.1B	$85.3B	$80.5B	$34.8B	$47.8B	$76.6B
Operating Margin	19.7%	12.5%	12.7%	16.1%	14.9%	6.7%	9.7%	13.4%
Interest Expense	$3.7B	$2.8B	$3.2B	$3.2B	$3.4B	$4.0B	$3.1B	$5.7B
Income Before Tax	$57.5B	-$28.5B	$44.6B	$69.2B	$80.1B	$49.7B	$67.9B	$40.6B
Tax Expense	-$466M	$4.0B	$10.1B	$7.9B	$17.4B	-$19.7B	$14.6B	$4.2B
Net Income	$44.5B	-$27.7B	$26.2B	$38.9B	$40.1B	$69.9B	$35.3B	$34.1B
Net Margin	8.6%	-5.5%	5.4%	7.4%	7.4%	13.5%	7.2%	6.0%
EPS (Diluted)	$1088.00	$-676.96	$639.80	$950.92	$981.00	$2015.65	$838.76	$811.88
EBITDA	$116.1B	-$9.8B	$481.4B	$99.7B	$98.8B	$61.4B	$68.1B	$106.0B
Shares Outstanding	41M	41M	41M	41M	41M	32M	42M	42M

003090.KS KSC